SCHEMBL971026

SCHEMBL971026

CCCc1nc(C)c2c(Cl)nc3ccc(F)cc3n12

nearest known ligand 0.46

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 14/20 0.46
PDE2A O00408 8/20 0.45
PDE5A O76074 1/20 0.43
PDE4A P27815 1/20 0.43
PDE4D Q08499 1/20 0.43
PDE7A Q13946 1/20 0.43
PDE3A Q14432 1/20 0.43
PDE11A Q9HCR9 1/20 0.43
PDE7B Q9NP56 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL970643 0.90 PDE10A (0.57) PDE10APDE2APDE5APDE4APDE4D
SCHEMBL969580 0.85 PDE10A (0.46) PDE10APDE2APDE5APDE4APDE4D
SCHEMBL8042597 0.83 PDE10A (0.49) PDE10APDE2APDE5APDE4APDE4D
SCHEMBL971116 0.83 PDE10A (0.61) PDE10APDE2APDE5APDE4APDE4D
SCHEMBL3661392 0.82 PDE10A (0.58) PDE10APDE2APDE5APDE4APDE4D
SCHEMBL968994 0.82 PDE10A (0.51) PDE10APDE2APDE5APDE4APDE4D
SCHEMBL969869 0.79 PDE10A (0.58) PDE10APDE2APDE5APDE4APDE4D
SCHEMBL3662037 0.78 PDE10A (0.61) PDE10APDE2APDE5APDE3APDE11A
SCHEMBL3326097 0.77 PDE2A (0.53) PDE10APDE2APDE3A
SCHEMBL3665849 0.77 PDE10A (0.46) PDE10APDE2APDE5APDE4APDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875618-B2 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) WYETH (US) 2011-01-25 US disclosed
EP-2227472-A1 ARYL AND HETEROARYL FUSED IMIDAZO (1,5-A) PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 Elbion Gmbh (DE) 2010-09-15 EP disclosed
EP-2225248-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 Wyeth LLC (US) 2010-09-08 EP disclosed
WO-2009070584-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 WYETH (US) 2009-06-04 WO disclosed
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 ELBION GMBH (DE) 2009-06-04 US disclosed
WO-2009068320-A1 ARYL AND HETEROARYL FUSED IMIDAZO (1,5-A) PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 ELBION GMBH (DE) 2009-06-04 WO disclosed
US-20090143391-A1 Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10 ELBION GMBH (DE) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143391-A1 Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10 PDE12, PDE5A, PDE10A PDE10A 3/4885PDE2A 6/4885PDE5A 2/4885
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 PDE12, PDE5A, PDE10A PDE10A 3/4885PDE2A 6/4885PDE5A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.